CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
Authors:
- Elodie CoquanECElodie Coquan
- Pierre-Emmanuel BrachetPBPierre-Emmanuel Brachet
- Idlir LicajILIdlir Licaj
- Alexandra LeconteALAlexandra Leconte
- Marie CasteraMCMarie Castera
- Justine LequesneJLJustine Lequesne
- Emeline MeriauxEMEmeline Meriaux
- Isabelle BonnetIBIsabelle Bonnet
- Anais LelaidierALAnais Lelaidier
- Bénédicte ClarisseBCBénédicte Clarisse
- Florence JolyFJFlorence Joly
Open Access
- 25 September 2021
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-12
Abstract
Background: Cervical cancer is the tenth diagnosed cancer in the world. Early-stage and locally recurrent disease may be cured with radical surgery or chemo-radiotherapy. However, if disease persists or recurs, options are limited and the prognosis is poor. In addition to chemotherapy, bevacizumab, an antiangiogenic agent, has recently demonstrated its efficacy in this setting. Cabozantinib is an oral small molecule tyrosine kinase inhibitor that exhibits potent inhibitory activity against several receptor tyrosine kinases that are known to influence tumor growth, metastasis, and angiogenesis. The main targets of Cabozantinib are VEGFR2, MET and AXL. It is currently approved for the treatment of metastatic renal cell carcinoma, hepatocellular carcinoma and medullary thyroid carcinoma. Given its angiogenic properties associated with growth factor receptors inhibition, Cabozantinib represents a potential active treatment in cervical carcinoma. In this context, we propose to assess the efficacy and safety of cabozantinib monotherapy in advanced/metastatic cervical carcinoma (CC) after failure to platinum-based regimen treatment.Methods: This study is a single-arm two-stage multicenter phase II aiming to simultaneously assess efficacy and safety of Cabozantinib among advanced/metastatic cervical carcinoma (CC) after failure to platinum-based regimen treatment. The main criterion will be based on both safety and clinical efficacy by conducting a Bryant-and-Day design. Safety endpoint is the proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE V.5.0) occurring up to one month after the end of treatment. Efficacy endpoint is the proportion of patients with disease control rate 3 months after Cabozantinib initiation. A patients’ self-reported quality of life evaluation is also planned, as well as the investigation of nutritional outcomes. Cabozantinib will be administered at the daily dose of 60 mg given orally, without interruption until disease progression or discontinuation for any cause.Discussion: Cabozantinib is a promising drug for patients with advanced/metastatic cervical cancer where few therapeutics options are available after failure to platinum-based regimen metastatic CC. It appears challenging to assess the interest of Cabozantinib in this indication, taking into account the potential toxicity of the drug.Trial registration: NCT04205799, registered “2019 12 19”.Protocol version: Version 3.1 dated from 2020 08 31.Keywords
Funding Information
- Ipsen Pharma SAS
This publication has 37 references indexed in Scilit:
- Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer PatientsPLOS ONE, 2012
- Targeting MET in cancer: rationale and progressNature Reviews Cancer, 2012
- Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical CancerJournal of Clinical Oncology, 2010
- A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184Gynecologic Oncology, 2010
- Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2009
- Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2005
- Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupGynecologic Oncology, 2005
- Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2004
- A Phase II Study of Topotecan in Patients with Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group StudyGynecologic Oncology, 2001
- Sample size tables for exact single‐stage phase II designsStatistics in Medicine, 2001